Cargando…
Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study
INTRODUCTION: Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI Pr...
Autores principales: | Schoenberg, Paige, Edwards, O. Winslow, Merrill, Leland, Martinez, Cristian Acero, Stephenson, Rob, Sullivan, Patrick S., Jones, Jeb |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034617/ https://www.ncbi.nlm.nih.gov/pubmed/36951057 http://dx.doi.org/10.1002/jia2.26077 |
Ejemplares similares
-
Perceptions and Experiences of Returning Self-collected Specimens for HIV, Bacterial STI and Potential PrEP Adherence Testing among Sexual Minority Men in the United States
por: Sharma, Akshay, et al.
Publicado: (2022) -
Interest in HIV Prevention Mobile Phone Apps: Focus Group Study With Sexual and Gender Minority Persons Living in the Rural Southern United States
por: Jones, Jeb, et al.
Publicado: (2022) -
Modeling the Impact of PrEP Programs for Adolescent Sexual Minority Males Based on Empirical Estimates for the PrEP Continuum of Care
por: Hamilton, Deven T., et al.
Publicado: (2020) -
The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020) -
“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
por: Pasipanodya, Elizabeth C., et al.
Publicado: (2021)